These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30404451)

  • 1. Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies.
    Dhanda G; Sarkar P; Samaddar S; Haldar J
    J Med Chem; 2019 Apr; 62(7):3184-3205. PubMed ID: 30404451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pursuit of next-generation glycopeptides: a journey with vancomycin.
    Acharya Y; Dhanda G; Sarkar P; Haldar J
    Chem Commun (Camb); 2022 Feb; 58(12):1881-1897. PubMed ID: 35043130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and study of antibacterial activities of antibacterial glycopeptide antibiotics conjugated with benzoxaboroles.
    Printsevskaya SS; Reznikova MI; Korolev AM; Lapa GB; Olsufyeva EN; Preobrazhenskaya MN; Plattner JJ; Zhang YK
    Future Med Chem; 2013 Apr; 5(6):641-52. PubMed ID: 23617428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in Glycopeptide Antibiotics.
    Blaskovich MAT; Hansford KA; Butler MS; Jia Z; Mark AE; Cooper MA
    ACS Infect Dis; 2018 May; 4(5):715-735. PubMed ID: 29363950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane Disruption and Enhanced Inhibition of Cell-Wall Biosynthesis: A Synergistic Approach to Tackle Vancomycin-Resistant Bacteria.
    Yarlagadda V; Samaddar S; Paramanandham K; Shome BR; Haldar J
    Angew Chem Int Ed Engl; 2015 Nov; 54(46):13644-9. PubMed ID: 26473305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
    Ślusarz R; Szulc M; Madaj J
    Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.
    van Groesen E; Innocenti P; Martin NI
    ACS Infect Dis; 2022 Aug; 8(8):1381-1407. PubMed ID: 35895325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria.
    Mühlberg E; Umstätter F; Kleist C; Domhan C; Mier W; Uhl P
    Can J Microbiol; 2020 Jan; 66(1):11-16. PubMed ID: 31545906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of an amphiphilic vancomycin aglycone derivative inspired by polymyxins: overcoming glycopeptide resistance in Gram-positive and Gram-negative bacteria in synergy with teicoplanin in vitro.
    Szűcs Z; Bereczki I; Fenyvesi F; Herczegh P; Ostorházi E; Borbás A
    Sci Rep; 2022 Dec; 12(1):20921. PubMed ID: 36463278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycopeptide resistance: Links with inorganic phosphate metabolism and cell envelope stress.
    Santos-Beneit F; Ordóñez-Robles M; Martín JF
    Biochem Pharmacol; 2017 Jun; 133():74-85. PubMed ID: 27894856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopeptide antibiotics and their novel semi-synthetic derivatives.
    Jeya M; Moon HJ; Lee KM; Kim IW; Lee JK
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1194-204. PubMed ID: 21470154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL; Yang G
    Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
    Boneca IG; Chiosis G
    Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.
    Zeng D; Debabov D; Hartsell TL; Cano RJ; Adams S; Schuyler JA; McMillan R; Pace JL
    Cold Spring Harb Perspect Med; 2016 Dec; 6(12):. PubMed ID: 27663982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopeptide Antibiotic To Overcome the Intrinsic Resistance of Gram-Negative Bacteria.
    Yarlagadda V; Manjunath GB; Sarkar P; Akkapeddi P; Paramanandham K; Shome BR; Ravikumar R; Haldar J
    ACS Infect Dis; 2016 Feb; 2(2):132-9. PubMed ID: 27624964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycopeptide antibiotic biosynthesis.
    Yim G; Thaker MN; Koteva K; Wright G
    J Antibiot (Tokyo); 2014 Jan; 67(1):31-41. PubMed ID: 24220108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.